Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Sees Large Decrease in Short Interest

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the recipient of a large decline in short interest in September. As of September 15th, there was short interest totaling 4,130 shares, a decline of 36.9% from the August 31st total of 6,541 shares. Based on an average daily volume of 5,757 shares, the short-interest ratio is presently 0.7 days. Currently, 0.3% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Fidelity Disruptive Medicine ETF stock. Citadel Advisors LLC bought a new stake in shares of Fidelity Disruptive Medicine ETF (NASDAQ:FMED) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 9,896 shares of the company’s stock, valued at approximately $282,000. Citadel Advisors LLC owned approximately 0.62% of Fidelity Disruptive Medicine ETF at the end of the most recent reporting period.

Fidelity Disruptive Medicine ETF Trading Up 0.5%

NASDAQ FMED opened at $31.82 on Friday. The stock has a market capitalization of $50.91 million, a price-to-earnings ratio of 41.33 and a beta of 0.76. The stock has a 50-day moving average of $31.04 and a 200 day moving average of $27.71. Fidelity Disruptive Medicine ETF has a twelve month low of $23.48 and a twelve month high of $32.89.

Fidelity Disruptive Medicine ETF Company Profile

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.